Transforming growth factor beta receptor type 2 mRNA (TGFBR2 mRNA)

Transforming growth factor beta receptor type 2 (TGFBR2) mRNA is the transcript responsible for the synthesis of the TGFBR2 protein, a key transmembrane serine/threonine kinase. This receptor plays a central role in the TGF-beta signaling pathway, which regulates critical cellular functions such as proliferation, differentiation, and apoptosis (NCBI Gene ID: 7048). In oncology, the mRNA's role is complex; it acts as a tumor suppressor in early-stage cancers but facilitates metastasis and immune suppression in advanced stages (PubMed: 25611381). Dysregulation of TGFBR2 mRNA is also a primary driver of various fibrotic conditions, including pulmonary and renal fibrosis, by promoting the production of extracellular matrix (PubMed: 30233353). Therapeutic targeting of the mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) aims to silence receptor production at the pre-translational level. This strategy is designed to inhibit the SMAD-dependent signaling cascade more selectively than traditional small molecule inhibitors. Current research focuses on using these mRNA-targeted agents to overcome immune evasion in the tumor microenvironment and to halt the progression of chronic fibrotic diseases (PubMed: 28923825).

Other names

TGF-beta receptor type II mRNATGFB-R2 mRNATbetaR-II mRNATGFR-2 mRNATGFBR2 transcript

RNA interference (RNAi) or antisense-mediated degradation of mRNA to prevent translation of the TGFBR2 protein, thereby inhibiting TGF-beta signaling.